Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 4:36 pm Sale | 13G | Sigilon Therapeutics Inc. SGTX | Flagship Ventures Fund V L.P. | 0 0.000% | -10,370,369 (Position Closed) | View |
| 2023-08-14 4:30 pm Purchase | 13D | Sigilon Therapeutics Inc. SGTX | ELI LILLY & Co LLY | 100 100.000% | 100 (New Position) | View |
| 2023-07-07 4:33 pm Sale | 13D | Sigilon Therapeutics Inc. SGTX | ELI LILLY & Co LLY | 1,008,830 40.300% | -1,735,613 (-63.24%) | View |
| 2022-07-08 4:56 pm Sale | 13G | Sigilon Therapeutics Inc. SGTX | BlackRock Inc. BLK | 1,066,092 3.300% | -670,465 (-38.61%) | View |
| 2022-02-04 4:12 pm Purchase | 13G | Sigilon Therapeutics Inc. SGTX | BlackRock Inc. BLK | 1,736,557 5.400% | 1,736,557 (New Position) | View |
| 2021-02-16 5:06 pm Purchase | 13G | Sigilon Therapeutics Inc. SGTX | Flagship Ventures Fund V L.P. | 10,370,369 33.200% | 10,370,369 (New Position) | View |
| 2021-02-12 4:31 pm Purchase | 13G | Sigilon Therapeutics Inc. SGTX | ELI LILLY & Co LLY | 2,744,443 8.800% | 2,744,443 (New Position) | View |